カテゴリー： 世界

細胞＆遺伝子治療CDMO市場-規模、シェア、動向分析レポート、予測2024-2030

【英語タイトル】Cell And Gene Therapy CDMO Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2024 - 2030

Grand View Researchが出版した調査資料（GVR-4-68040-167-4）・商品コード：GVR-4-68040-167-4
・発行会社（調査会社）：Grand View Research
・発行日：2023年12月
・ページ数：195
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後6営業日）
・調査対象地域：グローバル
・産業分野：医療・バイオ
◆販売価格オプション（消費税別）
Individual UserUSD5,950 ⇒換算￥844,900見積依頼/購入/質問フォーム
Team LicenseUSD6,950 ⇒換算￥986,900見積依頼/購入/質問フォーム
Enterprise LicenseUSD8,950 ⇒換算￥1,270,900見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

The global cell and gene therapy CDMO market size was estimated at USD 4.99 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 27.9% from 2024 to 2030. The market is experiencing robust growth during the analysis period, fueled by an expanding portfolio of cell and gene therapy products, increased researcher attention on rare diseases, substantial investments from both public and private sectors in research and development, rising demand for outsourced services related to cell and gene therapies, increasing prevalence of chronic ailments such as cancer, a surge in mergers & acquisitions activities, and ongoing technological innovations throughout the cell and gene therapy development process.

Increased R&D funding and investments in cell and gene therapeutics (CGT) is a crucial trend in the biotechnology and pharmaceutical industries. Cell and gene therapies hold significant potential in treating a wide range of diseases, including cancer, genetic disorders, and certain infectious diseases. Hence, owing to the great potential of these therapeutics, there has been a considerable increase in interest from both private and public sectors in the development and discovery of innovative cell and gene therapies. Most big pharmaceutical companies are now investing in CGT to create a strong position in the market. There has been a considerable increase in venture capital investments, especially in the life sciences sector.

For instance, a pharmaceutical giant, Charles River Laboratories stated that the life sciences industry has witnessed a consistent average growth rate of 18% in investments from 2010 to 2021. The growth rate in gene therapy during this same timeframe has also increased to approximately 59%.

The market experienced disruptions during the initial phases of the COVID-19 pandemic, mainly due to a slowdown in overall clinical trial activities. The pandemic significantly affected supply chain management, emerging as a primary factor hindering market growth. The substantial impact was attributed to a lack of demand forecasting and feasibility planning. Lockdowns and restrictions imposed in the early stages of the pandemic raised concerns about logistics and transportation, leading to delays and temporary suspensions of clinical trials.

However, the outbreak of COVID-19 has accelerated certain new models in the cell and gene therapy CDMO industry to ease the crisis and cope with changing trends. Virtual trials are gradually gaining popularity and are expected to grow considerably in the coming years. The pandemic led to certain restrictions, such as social distancing and travel restrictions, owing to which around 80.00% of sites were temporarily suspended or put on hold at least one clinical trial. Therefore, to avoid such situations, virtual trials are gradually being adopted, which allow the implementation of innovative approaches to trials and help ensure a better patient experience. Furthermore, the CDMOs eradicated the negative impact of the COVID-19 pandemic by involving in in-organic strategic initiatives such as mergers, partnerships, and acquisitions. This helped them in sales rebound by 2021.

[Key Companies & Market Share Insights]
The major players operating across the market are focused on adopting in-organic strategic initiatives such as mergers, partnerships, acquisitions, etc. Moreover, companies focus on technological innovations to augment their market position. For instance, in September 2023, Charles River Laboratories unveiled its new technology Lentivation lentiviral vector (LVV) manufacturing platform. This platform is designed to streamline the manufacturing timelines for gene and gene-modified cell therapies, potentially reducing them by up to 60%, resulting in fewer than seven months compared to conventional manufacturing workflows.

Key Cell And Gene Therapy CDMO Companies:
Lonza
Catalent, Inc
Cytiva
Samsung Biologics
Thermo Fisher Scientific Inc.
Novartis AG
WuXi AppTec
AGC Biologics
OmniaBio
Rentschler Biopharma SE
Charles River Laboratories

❖ レポートの目次 ❖

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.1.2. Phase
1.1.3. Product Type
1.1.4. Indication
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.4.1. Objective – 1
1.4.2. Objective – 2
1.4.3. Objective – 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Parent Market Analysis
1.10. List Of Secondary Sources
1.11. List Of Abbreviations
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Cell and Gene Therapy CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing pipeline of cell and gene therapy products to boost the market growth
3.2.1.2. Increasing investments and R&D funding for the development of cell and gene therapeutics
3.2.1.3. Technological innovations across the cell & gene therapy development process
3.2.1.4. Increasing mergers & acquisitions in the cell and gene therapy industry
3.2.2. Market Restraint Analysis
3.2.2.1. Compliance with strict regulatory requirements
3.2.2.2. High development costs of CGT products
3.3. Cell and Gene Therapy CDMO Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat Of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Cell and Gene Therapy CDMO Market: Phase Estimates & Trend Analysis
4.1. Cell and Gene Therapy CDMO Market, By Phase: Segment Dashboard
4.2. Cell and Gene Therapy CDMO Market, By Phase: Movement Analysis
4.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Phase, 2018 – 2030
4.3.1. Pre-clinical
4.3.1.1. Pre-clinical Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
4.3.2. Clinical
4.3.2.1. Clinical Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
Chapter 5. Cell and Gene Therapy CDMO Market: Product Type Estimates & Trend Analysis
5.1. Cell and Gene Therapy CDMO Market, By Product Type: Segment Dashboard
5.2. Cell and Gene Therapy CDMO Market, By Product Type: Movement Analysis
5.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Product Type, 2018 – 2030
5.3.1. Gene Therapy
5.3.1.1. Gene Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
5.3.1.2. Ex-vivo
5.3.1.2.1. Ex-vivo Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
5.3.1.3. In-vivo
5.3.1.3.1. In-vivo Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
5.3.2. Gene-Modified Cell Therapy
5.3.2.1. Gene-Modified Cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
5.3.2.2. CAR T-cell therapies
5.3.2.2.1. CAR T-cell therapies Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
5.3.2.3. CAR-NK cell therapy
5.3.2.3.1. CAR-NK cell therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
5.3.2.4. TCR-T cell therapy
5.3.2.4.1. TCR-T cell therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
5.3.2.5. Others
5.3.2.5.1. Others cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
5.3.3. Cell Therapy
5.3.3.1. Cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
Chapter 6. Cell and Gene Therapy CDMO Market: Indication Estimates & Trend Analysis
6.1. Cell and Gene Therapy CDMO Market, By Indication: Segment Dashboard
6.2. Cell and Gene Therapy CDMO Market, By Indication: Movement Analysis
6.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Indication, 2018 – 2030
6.3.1. Oncology
6.3.1.1. Oncology Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
6.3.2. Infectious Diseases
6.3.2.1. Infectious Diseases Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
6.3.3. Neurological Disorders
6.3.3.1. Neurological Disorders Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
6.3.4. Rare Diseases
6.3.4.1. Rare Diseases Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
6.3.5. Others
6.3.5.1. Others Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
Chapter 7. Cell and Gene Therapy CDMO Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. North America
7.4.1. Market Estimates and Forecast, 2018 – 2030 (Revenue, USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. U.S. Market Estimates and Forecasts, 2018 – 2030
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Canada Market Estimates and Forecasts, 2018 – 2030
7.5. Europe
7.5.1. UK
7.5.1.1. Key Country Dynamics
7.5.1.2. Competitive Scenario
7.5.1.3. Regulatory Framework
7.5.1.4. UK Market Estimates and Forecasts, 2018 – 2030
7.5.2. Germany
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Germany Market Estimates and Forecasts, 2018 – 2030
7.5.3. France
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. France Market Estimates and Forecasts, 2018 – 2030
7.5.4. Italy
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Italy Market Estimates and Forecasts, 2018 – 2030
7.5.5. Spain
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Framework
7.5.5.4. Spain Market Estimates and Forecasts, 2018 – 2030
7.5.6. Denmark
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Framework
7.5.6.4. Denmark Market Estimates and Forecasts, 2018 – 2030
7.5.7. Sweden
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Framework
7.5.7.4. Sweden Market Estimates and Forecasts, 2018 – 2030
7.5.8. Norway
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Framework
7.5.8.4. Norway Market Estimates and Forecasts, 2018 – 2030
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key Country Dynamics
7.6.1.2. Competitive Scenario
7.6.1.3. Regulatory Framework
7.6.1.4. Japan Market Estimates and Forecasts, 2018 – 2030
7.6.2. India
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. India Market Estimates and Forecasts, 2018 – 2030
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. China Market Estimates and Forecasts, 2018 – 2030
7.6.4. South Korea
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. South Korea Market Estimates and Forecasts, 2018 – 2030
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Australia Market Estimates and Forecasts, 2018 – 2030
7.6.6. Thailand
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Framework
7.6.6.4. Thailand Market Estimates and Forecasts, 2018 – 2030
7.7. Latin America
7.7.1. Brazil
7.7.1.1. Key Country Dynamics
7.7.1.2. Competitive Scenario
7.7.1.3. Regulatory Framework
7.7.1.4. Brazil Market Estimates and Forecasts, 2018 – 2030
7.7.2. Mexico
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. Mexico Market Estimates and Forecasts, 2018 – 2030
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Argentina Market Estimates and Forecasts, 2018 – 2030
7.8. MEA
7.8.1. South Africa
7.8.1.1. Key Country Dynamics
7.8.1.2. Competitive Scenario
7.8.1.3. Regulatory Framework
7.8.1.4. South Africa Market Estimates and Forecasts, 2018 – 2030
7.8.2. Saudi Arabia
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 – 2030
7.8.3. UAE
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. UAE Market Estimates and Forecasts, 2018 – 2030
7.8.4. Kuwait
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Framework
7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 – 2030
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.1.1. Innovators
8.1.2. Market Leaders
8.1.3. Emerging Players
8.1.4. Company Market Share Analysis, 2023
8.2. Company Profiles
8.2.1. Lonza
8.2.1.1. Company Overview
8.2.1.2. Financial Performance
8.2.1.3. Service Benchmarking
8.2.1.4. Strategic Initiatives
8.2.2. Catalent, Inc
8.2.2.1. Company Overview
8.2.2.2. Financial Performance
8.2.2.3. Service Benchmarking
8.2.2.4. Strategic Initiatives
8.2.3. Cytiva
8.2.3.1. Company Overview
8.2.3.2. Financial Performance
8.2.3.3. Service Benchmarking
8.2.3.4. Strategic Initiatives
8.2.4. Samsung Biologics
8.2.4.1. Company Overview
8.2.4.2. Financial Performance
8.2.4.3. Service Benchmarking
8.2.4.4. Strategic Initiatives
8.2.5. Thermo Fisher Scientific Inc.
8.2.5.1. Company Overview
8.2.5.2. Financial Performance
8.2.5.3. Service Benchmarking
8.2.5.4. Strategic Initiatives
8.2.6. Novartis AG
8.2.6.1. Company Overview
8.2.6.2. Financial Performance
8.2.6.3. Service Benchmarking
8.2.6.4. Strategic Initiatives
8.2.7. WuXi AppTec
8.2.7.1. Company Overview
8.2.7.2. Financial Performance
8.2.7.3. Service Benchmarking
8.2.7.4. Strategic Initiatives
8.2.8. AGC Biologics
8.2.8.1. Company Overview
8.2.8.2. Financial Performance
8.2.8.3. Service Benchmarking
8.2.8.4. Strategic Initiatives
8.2.9. OmniaBio
8.2.9.1. Company Overview
8.2.9.2. Financial Performance
8.2.9.3. Service Benchmarking
8.2.9.4. Strategic Initiatives
8.2.10. Rentschler Biopharma SE
8.2.10.1. Company Overview
8.2.10.2. Financial Performance
8.2.10.3. Service Benchmarking
8.2.10.4. Strategic Initiatives
8.2.11. Charles River Laboratories
8.2.11.1. Company Overview
8.2.11.2. Financial Performance
8.2.11.3. Service Benchmarking
8.2.11.4. Strategic Initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 North America Cell and Gene Therapy CDMO market, by region, 2018 – 2030 (USD Million)
Table 4 North America Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 5 North America Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 6 North America Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 7 North America Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 8 North America Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 9 U.S. Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 10 U.S. Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 11 U.S. Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 12 U.S. Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 13 U.S. Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 14 Canada Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 15 Canada Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 16 Canada Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 17 Canada Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 18 Canada Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 19 Europe Cell and Gene Therapy CDMO market, by region, 2018 – 2030 (USD Million)
Table 20 Europe Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 21 Europe Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 22 Europe Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 23 Europe Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 24 Europe Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 25 UK Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 26 UK Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 27 UK Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 28 UK Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 29 UK Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 30 Germany Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 31 Germany Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 32 Germany Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 33 Germany Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 34 Germany Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 35 France Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 36 France Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 37 France Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 38 France Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 39 France Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 40 Italy Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 41 Italy Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 42 Italy Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 43 Italy Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 44 Italy Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 45 Spain Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 46 Spain Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 47 Spain Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 48 Spain Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 49 Spain Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 50 Denmark Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 51 Denmark Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 52 Denmark Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 53 Denmark Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 54 Denmark Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 55 Sweden Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 56 Sweden Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 57 Sweden Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 58 Sweden Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 59 Sweden Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 60 Norway Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 61 Norway Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 62 Norway Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 63 Norway Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 64 Norway Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 65 Asia Pacific Cell and Gene Therapy CDMO market, by region, 2018 – 2030 (USD Million)
Table 66 Asia Pacific Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 67 Asia Pacific Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 68 Asia Pacific Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 69 Asia Pacific Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 70 Asia Pacific Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 71 China Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 72 China Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 73 China Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 74 China Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 75 China Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 76 Japan Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 77 Japan Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 78 Japan Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 79 Japan Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 80 Japan Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 81 India Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 82 India Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 83 India Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 84 India Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 85 India Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 86 Australia Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 87 Australia Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 88 Australia Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 89 Australia Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 90 Australia Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 91 South Korea Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 92 South Korea Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 93 South Korea Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 94 South Korea Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 95 South Korea Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 96 Thailand Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 97 Thailand Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 98 Thailand Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 99 Thailand Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 100 Thailand Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 101 Latin America Cell and Gene Therapy CDMO market, by region, 2018 – 2030 (USD Million)
Table 102 Latin America Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 103 Latin America Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 104 Latin America Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 105 Latin America Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 106 Latin America Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 107 Brazil Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 108 Brazil Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 109 Brazil Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 110 Brazil Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 111 Brazil Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 112 Mexico Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 113 Mexico Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 114 Mexico Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 115 Mexico Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 116 Mexico Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 117 Argentina Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 118 Argentina Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 119 Argentina Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 120 Argentina Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 121 Argentina Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 122 Middle East and Africa Cell and Gene Therapy CDMO market, by region, 2018 – 2030 (USD Million)
Table 123 Middle East and Africa Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 124 Middle East and Africa Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 125 Middle East and Africa Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 126 Middle East and Africa Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 127 Middle East and Africa Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 128 South Africa Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 129 South Africa Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 130 South Africa Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 131 South Africa Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 132 South Africa Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 133 Saudi Arabia Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 134 Saudi Arabia Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 135 Saudi Arabia Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 136 Saudi Arabia Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 137 Saudi Arabia Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 138 UAE Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 139 UAE Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 140 UAE Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 141 UAE Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 142 UAE Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)
Table 143 Kuwait Cell and Gene Therapy CDMO market, by Product Type, 2018 – 2030 (USD Million)
Table 144 Kuwait Cell and Gene Therapy CDMO market, by Gene-Modified Cell Therapy, 2018 – 2030 (USD Million)
Table 145 Kuwait Cell and Gene Therapy CDMO market, by Gene Therapy, 2018 – 2030 (USD Million)
Table 146 Kuwait Cell and Gene Therapy CDMO market, by Phase, 2018 – 2030 (USD Million)
Table 147 Kuwait Cell and Gene Therapy CDMO market, by Indication, 2018 – 2030 (USD Million)



★調査レポート[細胞＆遺伝子治療CDMO市場-規模、シェア、動向分析レポート、予測2024-2030] (コード：GVR-4-68040-167-4)販売に関する免責事項を必ずご確認ください。
★調査レポート[細胞＆遺伝子治療CDMO市場-規模、シェア、動向分析レポート、予測2024-2030]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 日本の医薬品開発製造受託機関（CDMO）市場規模、シェア、動向分析レポート、予測2023-2030
  • 先進治療薬CDMOの世界市場：現状分析・予測（2022年～2028年）
  • 標的タンパク質分解市場2020-2030
  • タイの脳健康サプリメント市場 (2024-2030)
  • 細胞・遺伝子治療製造サービスの世界市場レポート（2024年）
  • Interstitial Cystitis Market Insight, Epidemiology and Market Forecast -2030
  • ガンマブチロラクトンの世界市場2020-2030
  • ウイルスベクター製造市場レポート：2030年までの動向、予測、競合分析
  • 細胞治療の世界市場
  • 幹細胞治療市場：2019-2020年と2031年までの世界予測

    • ◆H&Iグローバルリサーチのお客様（例）◆